Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 16-week, Prospective, Open Label, Multicenter Study to Evaluate the Effectiveness and Safety of Rasilez® (Aliskiren) Monotherapy or in Addition With Hydrochlorothiazide 12.5 mg or 25 mg in Patients With Hypertension Stage I and II

NCT01056731 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT01056731
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01056731 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 16-week, Prospective, Open Label, Multicenter Study to Evaluate the Effectiveness and Safety of Rasilez® (Aliskiren) Monotherapy or in Addition With Hydrochlorothiazide 12.5 mg or 25 mg in Patients With Hypertension Stage I and II
Lead sponsor
Novartis
Phase
Phase 4
Overall status
Completed
Start date
February 28, 2010
Completion date
October 31, 2011
Enrollment
253 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

high blood pressure